# Scilex Holding Co (SCLX)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/scilex-holding-co/ JSON: https://steadybase.io/company/scilex-holding-co.json Checked Nov 10, 2026. Latest filing read: Aug 14, 2026.

## Company

- Legal name: Scilex Holding Co
- Ticker: SCLX, SCLXW (Nasdaq, Nasdaq)
- SEC CIK: 0001820190
- Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
- Headquarters: Palo Alto, CA
- Fiscal year ends: December 31
- SEC filer category: <br>Emerging growth company
- Website: scilexholding.com
- LinkedIn: https://www.linkedin.com/company/scilex-pharmaceuticals
- Next earnings date: Nov 13, 2026

## Key facts

- Revenue: $30.3M for the fiscal year ended Dec 31, 2025 (10-K filed Apr 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/0001193125-26-151455-index.html
- Operating income: -$346.0M for the fiscal year ended Dec 31, 2025 (10-K filed Apr 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/0001193125-26-151455-index.html
- Net income: -$374.1M for the fiscal year ended Dec 31, 2025 (10-K filed Apr 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/0001193125-26-151455-index.html
- SG&A: $266.9M for the fiscal year ended Dec 31, 2025 (10-K filed Apr 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/0001193125-26-151455-index.html
- Employees: 34 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/sclx-20251231.htm
- Shares outstanding: 8,493,000 as of Aug 10, 2026 (10-Q filed Aug 14, 2026). Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526352464/0001193125-26-352464-index.html
- Auditor: Bpm LLP, Walnut Creek, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/sclx-20251231.htm

## Business

We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/sclx-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $30.3M | -$346.0M | -$374.1M | $266.9M |
| Dec 31, 2024 | $56.6M | -$83.4M | -$72.8M | $119.0M |
| Dec 31, 2023 | $46.7M | -$105.4M | -$114.3M | $119.6M |
| Dec 31, 2022 | $38.0M | -$50.6M | -$23.4M | $64.9M |
| Dec 31, 2021 | $31.3M | -$35.8M | -$88.4M | $50.6M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/scilex-holding-co.json

## Officers and directors

- Henry Ji, Exec Chair, CEO and President. Source: Form 4 filed Apr 20, 2026, https://www.sec.gov/Archives/edgar/data/1820190/000119312526162846/0001193125-26-162846-index.htm
- Stephen Hoi Ma, CFO, COO and Secretary. Source: Form 4 filed Apr 20, 2026, https://www.sec.gov/Archives/edgar/data/1820190/000119312526162857/0001193125-26-162857-index.htm
- Stephen Ma, Chief Financial Officer. Source: 10-K filed Apr 10, 2026, https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/sclx-20251231.htm
- Dorman Followwill, Board member (per proxy). Source: DEF 14A filed Apr 30, 2026, https://www.sec.gov/Archives/edgar/data/1820190/000119312526197717/d146109ddef14a.htm
- Jay Chun, M.D., Ph.D., Board member (per proxy). Source: DEF 14A filed Apr 30, 2026, https://www.sec.gov/Archives/edgar/data/1820190/000119312526197717/d146109ddef14a.htm
- Yue Alexander Wu, Ph.D., Board member (per proxy). Source: DEF 14A filed Apr 30, 2026, https://www.sec.gov/Archives/edgar/data/1820190/000119312526197717/d146109ddef14a.htm
- Henry Ji, Ph.D., Board member (per proxy). Source: DEF 14A filed Nov 7, 2025, https://www.sec.gov/Archives/edgar/data/1820190/000119312525272322/d97653ddef14a.htm

## Recent 8-K events

- Sep 29, 2026: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526407333/sclx-20260925.htm
- Aug 12, 2026: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526347186/sclx-20260808.htm
- Jul 22, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.01, Completion of acquisition or disposition of assets; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526312591/sclx-20260718.htm
- Jul 6, 2026: Item 1.01, Entry into a material definitive agreement; Item 3.02, Unregistered sales of equity securities; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526295493/sclx-20260703.htm
- Jun 29, 2026: Item 1.01, Entry into a material definitive agreement; Item 3.02, Unregistered sales of equity securities. Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526288677/sclx-20260624.htm
- Jun 24, 2026: Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526281213/sclx-20260624.htm
- May 11, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526216921/sclx-20260511.htm
- May 5, 2026: Item 1.01, Entry into a material definitive agreement; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526205839/sclx-20260504.htm
- Apr 28, 2026: Item 1.01, Entry into a material definitive agreement. Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526187620/sclx-20260426.htm
- Mar 13, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1820190/000119312526105675/sclx-20260313.htm

## Latest filings

- 8-K filed Sep 29, 2026: https://www.sec.gov/Archives/edgar/data/1820190/000119312526407333/sclx-20260925.htm
- 10-K filed Apr 10, 2026: https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/sclx-20251231.htm
- 10-Q filed Aug 14, 2026: https://www.sec.gov/Archives/edgar/data/1820190/000119312526352464/sclx-20260630.htm
- DEF 14A filed Apr 30, 2026: https://www.sec.gov/Archives/edgar/data/1820190/000119312526197717/d146109ddef14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/